Health care costs and resource use of managing hemophilia A: A targeted literature review

Hemophilia A (HA) is a rare genetic condition affecting 32,000 male patients in the United States. Plasma-derived and recombinant clotting factors reflect standard of care. Extended half-life products, newly approved nonfactor agents (eg, emicizumab), and gene therapies in development are contributi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of managed care & specialty pharmacy 2023-06, Vol.29 (6), p.647-658
Main Authors: Chen, Yilin, Cheng, Spencer J, Thornhill, Tyler, Solari, Paul, Sullivan, Sean D
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hemophilia A (HA) is a rare genetic condition affecting 32,000 male patients in the United States. Plasma-derived and recombinant clotting factors reflect standard of care. Extended half-life products, newly approved nonfactor agents (eg, emicizumab), and gene therapies in development are contributing to changes in care management. With new therapies, the impact on costs needs to be better understood. We have summarized the published literature on the substantial costs and resource use of managing HA in the United States.
ISSN:2376-0540
2376-1032
DOI:10.18553/jmcp.2023.29.6.647